Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 10, 2011 - Issue 4
Submit an article Journal homepage
563
Views
22
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

Safety of rasagiline for the treatment of Parkinson's disease

Santiago Perez-Lloret University Hospital and University of Toulouse III, Department of Clinical Pharmacology, France and INSERM CIC-9302 and UMR-825, 37 Allées Jules Guesde, 31000, Toulouse, France+33 5 61 14 59 62; +33 5 61 14 56 42; [email protected]; University Hospital and University of Toulouse III, Department of Neurosciences, France and INSERM CIC-9302 and UMR-825, 37 Allées Jules Guesde, 31000, Toulouse, France; Clinical Pharmacology Center, Raul Carrea Institute for Neurological Research, Buenos Aires, Argentina
, MD PhD &
Olivier Rascol University Hospital and University of Toulouse III, Department of Clinical Pharmacology, France and INSERM CIC-9302 and UMR-825, 37 Allées Jules Guesde, 31000, Toulouse, France+33 5 61 14 59 62; +33 5 61 14 56 42; [email protected]; University Hospital and University of Toulouse III, Department of Neurosciences, France and INSERM CIC-9302 and UMR-825, 37 Allées Jules Guesde, 31000, Toulouse, France
, MD PhD
Pages 633-643 | Published online: 01 Apr 2011

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Santiago Perez-Lloret & Olivier Rascol. (2016) The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics 16:3, pages 245-258.
Read now
Fabrizio Stocchi, Chiara Fossati & Margherita Torti. (2015) Rasagiline for the treatment of Parkinson’s disease: an update. Expert Opinion on Pharmacotherapy 16:14, pages 2231-2241.
Read now
Michele A Faulkner. (2014) Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease. Expert Opinion on Drug Safety 13:8, pages 1055-1069.
Read now

Articles from other publishers (19)

Miguel Reina, Eduardo Gabriel Guzmán‐López & Annia Galano. (2022) Computational design of rasagiline derivatives: Searching for enhanced antioxidant capability. International Journal of Quantum Chemistry 123:2.
Crossref
Destany K. Kwon, Mohit Kwatra, Jing Wang & Han Seok Ko. (2022) Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies. Cells 11:23, pages 3736.
Crossref
John P. M. Finberg. (2020) The discovery and development of rasagiline as a new anti-Parkinson medication. Journal of Neural Transmission 127:2, pages 125-130.
Crossref
De-Qi Jiang, Hua-Kun Wang, Yan Wang, Ming-Xing Li, Li-Lin Jiang & Yong Wang. (2019) Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review. Neurological Sciences 41:1, pages 101-109.
Crossref
Nicolas Venisse, Sandrine Venisse & Antoine Dupuis. 2018. Pharmacie Clinique et Thérapeutique. Pharmacie Clinique et Thérapeutique 611 625.e1 .
Hanjun Kim, Chae Won Lim, Il-soo Kim, Sun-jong Pyo, Mi-Jung Kim, Young-min Park & Seong-beom Koh. (2017) Hypersexuality Induced by Rasagiline Monotherapy in a Patinet with Parkinson’s Disease. Journal of the Korean Neurological Association 35:4, pages 235-236.
Crossref
Tauqir A. Nizami & Ruimao Hua. (2017) Silver-catalyzed chemoselective annulation of propargyl amines with alkynes for access to pyridines and pyrroles. Tetrahedron 73:42, pages 6080-6084.
Crossref
Gabriel Henrique Hawthorne, Marcelo Picinin Bernuci, Mariza Bortolanza, Vitor Tumas, Ana Carolina Issy & Elaine Del-Bel. (2016) Nanomedicine to Overcome Current Parkinson’s Treatment Liabilities: A Systematic Review. Neurotoxicity Research 30:4, pages 715-729.
Crossref
Ticiane C. de Souza, Thiago de S. Fonseca, Jessyca A. da Costa, Maria Valderez Ponte Rocha, Marcos Carlos de Mattos, Roberto Fernandez-Lafuente, Luciana R.B. Gonçalves & José C. S. dos Santos. (2016) Cashew apple bagasse as a support for the immobilization of lipase B from Candida antarctica: Application to the chemoenzymatic production of (R)-Indanol. Journal of Molecular Catalysis B: Enzymatic 130, pages 58-69.
Crossref
Thiago de Sousa Fonseca, Marcos Reinaldo da Silva, Maria da Conceição Ferreira de Oliveira, Telma Leda Gomes de Lemos, Ricardo de Araújo Marques & Marcos Carlos de Mattos. (2015) Chemoenzymatic synthesis of rasagiline mesylate using lipases. Applied Catalysis A: General 492, pages 76-82.
Crossref
Paul L. McCormack. (2014) Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease. CNS Drugs 28:11, pages 1083-1097.
Crossref
Guozhen Ma, Zhongqi Xu, Pengfei Zhang, Jinpo Liu, Xilin Hao, Jingping Ouyang, Ping Liang, Song You & Xian Jia. (2014) A Novel Synthesis of Rasagiline via a Chemoenzymatic Dynamic Kinetic Resolution. Organic Process Research & Development 18:10, pages 1169-1174.
Crossref
Dennys Reyes, Kateryna Kurako & Nestor Galvez-Jimenez. (2014) Rasagiline induced hypersexuality in Parkinson’s disease. Journal of Clinical Neuroscience 21:3, pages 507-508.
Crossref
Arif Dalvi, Kelly E. Lyons & Rajesh Pahwa. 2014. Inflammation in Parkinson's Disease. Inflammation in Parkinson's Disease 1 24 .
Lawrence W. Elmer. (2013) Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials. Parkinsonism & Related Disorders 19:11, pages 930-936.
Crossref
Sandro Zambito Marsala, Roberta Vitaliani, Daniele Volpe, Francesca Capozzoli, Luciana Baroni, Enrico Belgrado, Carlo Borsato, Manuela Gioulis, Corrado Marchini & Angelo Antonini. (2013) Rapid onset of efficacy of rasagiline in early Parkinson’s disease. Neurological Sciences 34:11, pages 2007-2013.
Crossref
Fanny Duval, Olivier Flabeau, Julien Razafimahefa, Umberto Spampinato & François Tison. (2013) Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: Possible serotonin syndrome. Movement Disorders 28:10, pages 1464-1464.
Crossref
Sheridan M. Hoy & Gillian M. Keating. (2012) Rasagiline. Drugs 72:5, pages 643-669.
Crossref
Matthias Löhle & Heinz Reichmann. (2011) Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. BMC Neurology 11:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.